1-3 of 3
Nicholas C. P. Cross
Close
Sort by
Journal Articles

Should we move to a genomic classification of neutrophilic myeloid neoplasms?

Clinical Trials & Observations
Gonzalo Carreño-Tarragona, Alberto Álvarez-Larrán, Juan Carlos Hernández-Boluda, Rosa Ayala, Nicholas C. P. Cross
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6705–6706.
https://doi.org/10.1182/bloodadvances.2023011103
Published: 2023
Journal Articles

CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

Clinical Trials & Observations
Gonzalo Carreño-Tarragona, Alberto Álvarez-Larrán, Claire Harrison, José Carlos Martínez-Ávila, Juan Carlos Hernández-Boluda, Francisca Ferrer-Marín, Deepti H. Radia, Elvira Mora, Sebastian Francis, Teresa González-Martínez, Kathryn Goddard, Manuel Pérez-Encinas, Srinivasan Narayanan, José María Raya, Vikram Singh, Xabier Gutiérrez, Peter Toth, Paula Amat-Martínez, Louisa Mcilwaine, Magda Alobaidi, Karan Mayani, Andrew McGregor, Ruth Stuckey, Bethan Psaila, Adrián Segura, Caroline Alvares, Kerri Davidson, Santiago Osorio, Robert Cutting, Caroline P. Sweeney, Laura Rufián, Laura Moreno, Isabel Cuenca, Jeffery Smith, María Luz Morales, Rodrigo Gil-Manso, Ioannis Koutsavlis, Lihui Wang, Adam J. Mead, María Rozman, Joaquín Martínez-López, Rosa Ayala, Nicholas C. P. Cross
Journal: Blood Advances
Blood Adv (2023) 7 (9): 1672–1681.
https://doi.org/10.1182/bloodadvances.2022008204
Published: 2023
Includes: Supplemental data
Journal Articles

Treatment-free remission in FIP1L1-PDGFRA –positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation

Clinical Trials & Observations
Georgia Metzgeroth, Juliana Schwaab, Nicole Naumann, Mohamad Jawhar, Torsten Haferlach, Alice Fabarius, Andreas Hochhaus, Wolf-Karsten Hofmann, Nicholas C. P. Cross, Andreas Reiter
Journal: Blood Advances
Blood Adv (2020) 4 (3): 440–443.
https://doi.org/10.1182/bloodadvances.2019001111
Published: 2020